Cost-Effectiveness of Treating Psoriasis Patients with Obesity/Overweight with Ixekizumab Plus Tirzepatide Versus Ixekizumab
SKIN The Journal of Cutaneous Medicine · 10.11.2026 · 10 (6) · s871
DOI: 10.25251/cxyqs283 ↗Kurz gefasst
Fachartikel in der Zeitschrift SKIN The Journal of Cutaneous Medicine, online erschienen am 10.11.2026. Verfasst von Joseph Merola und 6 weiteren Autor:innen. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objectives
To compare clinical and cost outcomes among moderate-severe psoriasis (PsO) patients (pts) with obesity or overweight (OO) treated with ixekizumab (IXE) and tirzepatide (TZP) to those treated with IXE alone.
Methods
A cost-effectiveness model was developed combining elements from two validated and published economic models for IXE and TZP. The TOGETHER-PsO phase 3b, randomized, open-label clinical study evaluated efficacy and safety of IXE concomitantly administered with TZP (versus IXE alone) in adults with moderate-to-severe plaque PsO and OO. Data from the TOGETHER-PsO clinical study was used to define the clinical profiles of PsO patients. The analysis compared IXE with TZP to IXE alone over a lifetime horizon. The model evaluated PsO outcomes, obesity-related complications (ORCs), quality adjusted-life years (QALYs), costs for disease-related health care services and treatments (2026 USD) from a societal perspective; and a 3% annual discount rate was applied to costs and effects. Input data were obtained from clinical trials (TOGETHER-PsO, SURMOUNT-4), real-world EHR data, and publications. Deterministic and probabilistic sensitivity analyses were performed to evaluate the robustness of results. Scenario analyses were run to examine impacts of inputs of interest over ranges of values.
Results
Lifetime analysis indicated patients on IXE plus TZP vs. IXE had lower BMI, more time with PASI75, PASI90, and PASI100 responses, fewer non-fatal myocardial infarction (21.6 fewer per 1,000 pts), fewer non-fatal strokes (19.9 fewer per 1,000 pts), fewer CV deaths (14.9 fewer per 1,000 pts), and fewer diabetes-related events and complications (2,357 fewer per 1,000 pts). IXE plus TZP compared to IXE alone produced an incremental cost-effectiveness ratio (ICER) of $145,489 (societal perspective). TZP acquisition costs ($94,366) were partially offset by lower ORC costs (-$17,112). Incremental total costs and QALYS were $103,513 and 0.711. One-way sensitivity analyses showed results were most sensitive to discount rates, IXE discontinuation rates, and the price of IXE (ICER range approximately $100,000-$176,000). Scenario analyses found that the combination was more cost-effective for subgroups with higher BMI, while shorter time horizons produced higher ICERs.
Conclusions
Combining IXE with TZP in PsO pts with OO was projected to yield fewer ORCs, resulting in more life years and QALYs. Cost-effectiveness analysis estimated an ICER below the $150,000 willingness-to-pay threshold in the lifetime base case.
Zitieren
APA
Merola, J., Burge, R., Klein, T., Hille, E., Ball, S., Sanden, L., & Blauvelt, A. (2026). Cost-Effectiveness of Treating Psoriasis Patients with Obesity/Overweight with Ixekizumab Plus Tirzepatide Versus Ixekizumab. SKIN The Journal of Cutaneous Medicine, 10(6), s871. https://doi.org/10.25251/cxyqs283
Vancouver
Merola J, Burge R, Klein T, Hille E, Ball S, Sanden L, et al. Cost-Effectiveness of Treating Psoriasis Patients with Obesity/Overweight with Ixekizumab Plus Tirzepatide Versus Ixekizumab. SKIN The Journal of Cutaneous Medicine. 2026;10(6):s871. doi:10.25251/cxyqs283
BibTeX
@article{Merola2026,
author = {Merola, Joseph and Burge, Russel and Klein, Timothy and Hille, Erik and Ball, Susan and Sanden, Louis and Blauvelt, Andrew},
title = {Cost-Effectiveness of Treating Psoriasis Patients with Obesity/Overweight with Ixekizumab Plus Tirzepatide Versus Ixekizumab},
journal = {SKIN The Journal of Cutaneous Medicine},
year = {2026},
volume = {10},
number = {6},
pages = {s871},
doi = {10.25251/cxyqs283}
}
EUVIMED